Bayer Shares Surge After Monsanto Appeal Win
By Helena Smolak
Bayer shares surged after a Washington appeal court reversed a $185 million verdict in favor of its Monsanto unit in a lawsuit related to alleged chemical contamination at a school in the state.
At 1041 GMT, shares of Bayer rose 4.6% to EUR28.60, and the stock has lost 15% year-to-date.
The former U.S. agrochemical company, which was acquired by Bayer in 2018, faced multiple lawsuits for alleged personal injuries related to PCB, now-prohibited chemicals called polychlorinated biphenyls that were sold by Monsanto spinoff Pharmacia. The court sent the case back to a trial court for potential further proceedings after it found some of the plaintiffs' evidence unreliable, among other errors, it said.
This litigation has the greatest risk for Bayer to result in a multi-billion dollar fine among the PCB lawsuits it faces, Jefferies analysts said in a note.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 02, 2024 07:10 ET (11:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back